Targeting ADAMS and ERBBs in lung cancer

被引：37

作者：

Hynes, Nancy E. ^{[1
]}

Schlange, Thomas ^{[1
]}

机构：

[1] Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland

来源：

CANCER CELL | 2006年 / 10卷 / 01期

关键词：

D O I：

10.1016/j.ccr.2006.06.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aberrant ERBB receptor activity contributes to the development of many human cancers. Receptor overexpression, kinase domain (KD) mutations, and autocrine ligand production contribute to ERBB activation in human tumors. ERBB-targeted tyrosine kinase inhibitors (TKIs) and monoclonal antibodies are used in cancer treatment; however, clinical hurdles, including patient selection and TKI resistance, need to be overcome in order to optimize therapy. This minireview will discuss recent findings on possible mechanisms leading to ERBB-targeted therapy resistance and potential means to overcome them.

引用

页码：7 / 11

页数：5

共 60 条

[21] Evaluation of the contributions of ADAMs 9, 12, 15, 17, and 19 to heart development and ectodomain shedding of neuregulins β1 and β2 [J].

Horiuchi, K ;

Zhou, HM ;

Kelly, K ;

Manova, K ;

Blobel, CP .

DEVELOPMENTAL BIOLOGY, 2005, 283 (02) :459-471

[22] ERBB receptors and cancer: The complexity of targeted inhibitors [J].

Hynes, NE ;

Lane, HA .

NATURE REVIEWS CANCER, 2005, 5 (05) :341-354

[23] The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies [J].

Ji, Hongbin ;

Li, Danan ;

Chen, Liang ;

Shimamura, Takeshi ;

Kobayashi, Susumu ;

McNamara, Kate ;

Mahmood, Umar ;

Mitchell, Albert ;

Sun, Yangping ;

Al-Hashem, Ruclayyah ;

Chirieac, Lucian R. ;

Padera, Robert ;

Bronson, Roderick T. ;

Kim, William ;

Janne, Pasi A. ;

Shapiro, Geoffrey I. ;

Tenen, Daniel ;

Johnson, Bruce E. ;

Weissleder, Ralph ;

Sharpless, Norman E. ;

Wong, Kwok-Kin .

CANCER CELL, 2006, 9 (06) :485-495

[24] Selecting patients for epidermal growth factor receptor inhibitor treatment:: A FISH story or a tale of mutations? [J].

Johnson, BE ;

Jänne, PAJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) :6813-6816

[25] EGFR mutation and resistance of non-small-cell lung cancer to gefitinib [J].

Kobayashi, S ;

Boggon, TJ ;

Dayaram, T ;

Janne, PA ;

Kocher, O ;

Meyerson, M ;

Johnson, BE ;

Eck, MJ ;

Tenen, DG ;

Halmos, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (08) :786-792

[26] Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib [J].

Kwak, EL ;

Sordella, R ;

Bell, DW ;

Godin-Heymann, N ;

Okimoto, RA ;

Brannigan, BW ;

Harris, PL ;

Driscoll, DR ;

Fidias, P ;

Lynch, TJ ;

Rabindran, SK ;

McGinnis, JP ;

Wissner, A ;

Sharma, SV ;

Isselbacher, KJ ;

Settleman, J ;

Haber, DA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (21) :7665-7670

[27] Trastuzumab in the treatment of advanced non-small-cell lung cancer: Is there a role? Focus on eastern cooperative oncology group study 2598 [J].

Langer, CJ ;

Stephenson, P ;

Thor, A ;

Vangel, M ;

Johnson, DH .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) :1180-1187

[28] Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma [J].

Lassus, Heini ;

Sihto, Harri ;

Leminen, Arto ;

Joensuu, Heikki ;

Isola, Jorma ;

Nupponen, Nina N. ;

Butzow, Ralf .

JOURNAL OF MOLECULAR MEDICINE-JMM, 2006, 84 (08) :671-681

[29] ERBB2 kinase domain mutation in the lung squamous cell carcinoma [J].

Lee, Jong Woo ;

Soung, Young Hwa ;

Kim, Su Young ;

Nam, Suk Woo ;

Park, Won Sang ;

Wang, Young Pil ;

Jo, Keon Hyun ;

Moon, Seok Whan ;

Song, Sang Yong ;

Lee, Jung Young ;

Yoo, Nam Jin ;

Lee, Sug Hyung .

CANCER LETTERS, 2006, 237 (01) :89-94

[30] Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas [J].

Lee, JW ;

Soung, YH ;

Seo, SH ;

Kim, SY ;

Park, CH ;

Wang, YP ;

Park, K ;

Nam, SW ;

Park, WS ;

Kim, SH ;

Lee, JY ;

Yoo, NJ ;

Lee, SH .

CLINICAL CANCER RESEARCH, 2006, 12 (01) :57-61

← 1 2 3 4 5 6 →